Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in Washington

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Guidance

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context emphasized broad awareness of wellness principles and the mechanisms by which various therapies interact with human physiology. Within this framework, discussions of pharmaceutical interventions naturally focused on intended benefits and standard risk profiles, providing a baseline for informed patient decision-making. As the informational landscape evolves, attention has increasingly shifted toward specific, real-world applications of widely prescribed medications. One such area involves the drug semaglutide, marketed under brand names including Ozempic, which has gained prominence for its role in managing type 2 diabetes and weight control. Concurrently, clinical observations have raised questions about potential gastrointestinal effects associated with its use, particularly delayed gastric emptying—a condition known as gastroparesis. This transition from general health education to a more targeted concern reflects a natural progression in scientific inquiry: moving from broad therapeutic principles to the nuanced experiences of individuals in occupational and daily life settings. For those who have used Ozempic and subsequently developed symptoms consistent with gastroparesis, understanding the legal landscape—including the statute of limitations in Washington—becomes a practical consideration. This pivot does not assert causation but rather acknowledges the need for careful documentation and timely action when adverse outcomes arise in the context of medication exposure.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacological action involves slowing gastric emptying, a mechanism that can, in susceptible individuals, contribute to the development of gastroparesis—a condition characterized by delayed gastric emptying in the absence of a mechanical obstruction. This narrative examines the clinical presentation of gastroparesis, the pharmacological link to Ozempic, and the risk and legal considerations for affected patients in Washington. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, weight loss, and severe quality-of-life impairment. In the context of Ozempic use, these symptoms may overlap with common gastrointestinal adverse reactions reported in clinical trials. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Pharmacological Mechanism and Clinical Evidence

The mechanistic pathway linking Ozempic to gastroparesis is rooted in its pharmacology. GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This effect is dose-dependent and can become pathological in some patients, leading to gastroparesis. The label also notes rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for clinically significant delayed gastric emptying. Additionally, the label lists gastrointestinal adverse reactions with a frequency of less than 5%, including dyspepsia (1.9%, 3.5%, 2.7% for placebo, 0.5 mg, 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these are not diagnostic of gastroparesis, they reflect the drug's impact on gastrointestinal motility. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a critical issue. The label does not explicitly list gastroparesis as a warning or adverse reaction, though it acknowledges delayed gastric emptying as a pharmacological effect. The warning about pulmonary aspiration due to retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98) implies recognition of significant gastric retention, but the label does not directly inform patients or prescribers about the risk of developing gastroparesis as a chronic condition. This gap may be relevant for patients who experience persistent symptoms after discontinuing the drug.

Legal Considerations for Washington Patients

For affected patients in Washington, attorney-related considerations involve the statute of limitations for filing a product liability claim. In Washington, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date the injury was discovered or reasonably should have been discovered. For Ozempic-associated gastroparesis, the timeline between exposure and documented harm is crucial. Symptoms may develop during dose escalation or after prolonged use, and diagnosis can be delayed due to overlap with common gastrointestinal side effects. Patients should document the start of Ozempic use, onset of symptoms, and any medical evaluations confirming gastroparesis. The statute of limitations may begin when a patient is diagnosed or when they reasonably should have connected their symptoms to the drug. Given the complexity, consulting an attorney promptly is advisable. In summary, Ozempic's mechanism of delaying gastric emptying can lead to gastroparesis in some patients, though the label does not explicitly warn of this risk. Clinical trial data show high rates of gastrointestinal adverse reactions, and postmarketing reports highlight the potential for significant gastric retention. Patients in Washington should be aware of the three-year statute of limitations and seek legal counsel if they suspect their gastroparesis is linked to Ozempic use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Washington?

In Washington, the statute of limitations for personal injury claims, including product liability for defective drugs, is generally three years from the date the injury was discovered or reasonably should have been discovered. For Ozempic-associated gastroparesis, this means the clock may start when a patient is diagnosed or when they reasonably should have connected their symptoms to the drug. It is crucial to consult an attorney promptly to ensure your claim is filed within the applicable time frame.

Does the Ozempic label warn about gastroparesis?

The Ozempic label does not explicitly list gastroparesis as a warning or adverse reaction. However, it acknowledges delayed gastric emptying as a pharmacological effect and includes a warning about pulmonary aspiration due to retained gastric contents in patients undergoing surgery (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This gap in explicit warning may be relevant for patients who develop chronic gastroparesis symptoms.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.